PMI21 / D&D Pharmatech - LARVOL DELTA

D&D Pharmatech "G alpha, Prostate Cancer Radiotherapy Treatment US Material and Use Patent Decision" [Google translation] (HIT News) - "D&D Pharmatech announced on the 18th that its affiliate, US-based G Alpha, has decided to register a US patent related to new substances and uses for its lead product, alpha radiotherapy candidate substance ZA-001 (product name PMI21), for the treatment of prostate cancer....By securing additional new patents, ZA-001 is able to maintain a broad source patent for various radiopharmaceutical candidates targeting PSMA through existing general purpose patents that it already holds, while the registration of this new patent enables more specific and direct intellectual property protection for ZA-001....Meanwhile, G alpha initiated early clinical trials for ZA-001 in China in July of last year to evaluate the drug’s safety and tolerability ahead of full-scale clinical trials in the United States, and plans to submit an IND in the United States this year based on the results of this clinical trial."

IND • Patent • Prostate Cancer

Precision Molecular Inc. Executes License for Exclusive Rights to an Astatine-211-Labeled Radiopharmaceutical Inhibitor of Prostate-Specific Membrane Antigen for Prostate Cancer Therapeutics (Businesswire) - "Precision Molecular, Inc...announced it has executed a licensing agreement with Johns Hopkins University for exclusive rights to an astatine-211-labeled inhibitor of prostate-specific membrane antigen (PSMA) which is typically elevated in prostate cancer cells. PMI is developing this astatine-211-labeled inhibitor of PSMA as PMI21 and expects to initiate clinical trials in the first half of next year...PMI21 is designed to target PSMA which is present at a low level in normal prostate tissue, but markedly elevated in prostate cancer cells."

Licensing / partnership • Genito-urinary Cancer • Oncology • Prostate Cancer